circumstances based on patient comorbidities and preference; combination therapy to optimize treatment effect; and consideration of goal-based treatment. Increased understanding of bone biology has led to the development of new therapeutic agents including ...
Lata PF,Elliott ME.Patient assessment in the diagnosis,prevention, and treatment of osteoporosis. Nutr Clin Pract . 2007Lata PF,Elliott ME. Patient assessment in the diagnosis, prevention,and treatment of osteoporosis[J]. Nutr Clin Pract,2007,22(3) :261 275....
Bisphosphonatescan be discontinued temporarily (“bisphosphonateholiday”) after3–5 yearsof treatment. Optimum duration ofbisphosphonateholiday is unclear: MonitorBMDusingDXAregularly and restart treatment ifBMDdeclines or if the patient sustains afracture. ...
(5) the joint(s) studied; (6) the cell type studied; (7) the drug studied; (8) drug route of administration, dosage, frequency, and treatment length; (9) methods of outcome assessment before and after treatment; (10) results/outcomes; and (11) association between treatment and results...
“dowager’s hump,” with an accompanying loss of height. A compression fracture of a vertebra may be signaled by a sudden sharp pain in the affected area after minimal or no trauma or by a sudden loss of height. It is common, however, for the patient not to recall pain or trauma ...
thereby augmenting the demand for osteoporosis treatment The market in the Asia Pacific is expected to grow at the highest CAGR. The growth in the CAGR is characterized by a rise in geriatric patient pool suffering from osteoporosis, increase in adoption of the new drug for the treatment of ost...
Central bone mass densitometry can determine bone mass, predict fracture risk, and influence patient and provider treatment decisions. Throughout life, everyone should practice a bone-healthy lifestyle, which emphasizes regular exercise, nutritious diet, tobacco avoidance, minimal alcohol use, and fall ...
This study was designed to complement these find- ings by assessing the reasons for non-treatment and the reasons for discontinuation from the patient's perspec- tive, with an emphasis on how the reasons for discon- tinuation interact with a patient's willingness to reini- tiate therapy. ...
4 Treatment The US Food and Drug Administration (FDA) has approved multiple drug therapies to reduce osteoporotic fractures, including bisphosphonates, parathyroid hormone, raloxifene, and estrogen. The choice of therapy should be an individual one based on the patient's clinical situation and the ...
Modafinil for persistent posttreatment fatigue: an open label study of 82 women with breast cancer. MASCC international symposia 2006, Abstract 11-070. 6) Internet or electronic resource AMA: helping doctors help patients [Internet]. Chicago: American Medical Association; c1995-2007 [cited 2007 ...